Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
Oncternal Therapeutics (ONCT) has announced its intention to voluntarily delist from Nasdaq and deregister with the SEC. The company plans to file a Form 25 Notification of Delisting on March 17, 2025, following Nasdaq's previous suspension of ONCT's common stock trading on December 3, 2024.
After the delisting becomes effective, Oncternal will file a Form 15 to deregister with the SEC, which will immediately suspend its obligations to file periodic reports including Forms 10-K, 10-Q, and 8-K. The company's duty to file other Exchange Act reports will terminate 90 days after Form 15 submission.
Oncternal Therapeutics (ONCT) ha annunciato la sua intenzione di ritirarsi volontariamente dal Nasdaq e di cessare la registrazione presso la SEC. L'azienda prevede di presentare un Modulo 25 di Notifica di Delisting il 17 marzo 2025, dopo la sospensione precedente del trading delle azioni comuni di ONCT avvenuta il 3 dicembre 2024.
Dopo che il delisting diventerà efficace, Oncternal presenterà un Modulo 15 per cessare la registrazione presso la SEC, il che sospenderà immediatamente i suoi obblighi di presentare rapporti periodici, inclusi i Moduli 10-K, 10-Q e 8-K. L'obbligo dell'azienda di presentare altri rapporti ai sensi dell'Exchange Act terminerà 90 giorni dopo la presentazione del Modulo 15.
Oncternal Therapeutics (ONCT) ha anunciado su intención de retirarse voluntariamente del Nasdaq y de cancelar su registro ante la SEC. La empresa planea presentar un Formulario 25 de Notificación de Delisting el 17 de marzo de 2025, tras la suspensión previa de la negociación de las acciones comunes de ONCT el 3 de diciembre de 2024.
Una vez que el delisting sea efectivo, Oncternal presentará un Formulario 15 para cancelar su registro ante la SEC, lo que suspenderá inmediatamente sus obligaciones de presentar informes periódicos, incluidos los Formularios 10-K, 10-Q y 8-K. La obligación de la empresa de presentar otros informes según la Ley de Bolsa terminará 90 días después de la presentación del Formulario 15.
Oncternal Therapeutics (ONCT)는 Nasdaq에서 자발적으로 상장 폐지하고 SEC에 등록 취소를 하겠다는 의사를 발표했습니다. 이 회사는 2025년 3월 17일에 ONCT의 보통주 거래가 2024년 12월 3일에 Nasdaq에서 이전에 중단된 후 상장 폐지 통지서인 Form 25를 제출할 계획입니다.
상장 폐지가 효력이 발생한 후 Oncternal은 SEC에 등록 취소를 위한 Form 15를 제출할 것이며, 이는 즉시 10-K, 10-Q 및 8-K 양식을 포함한 정기 보고서 제출 의무를 중단시킵니다. 회사의 Exchange Act에 따른 기타 보고서 제출 의무는 Form 15 제출 후 90일이 지나면 종료됩니다.
Oncternal Therapeutics (ONCT) a annoncé son intention de se retirer volontairement du Nasdaq et de se désinscrire auprès de la SEC. L'entreprise prévoit de déposer un Formulaire 25 de Notification de Retrait le 17 mars 2025, suite à la suspension précédente de la négociation des actions ordinaires d'ONCT le 3 décembre 2024.
Une fois le retrait effectif, Oncternal déposera un Formulaire 15 pour se désinscrire auprès de la SEC, ce qui suspendra immédiatement ses obligations de déposer des rapports périodiques, y compris les Formulaires 10-K, 10-Q et 8-K. L'obligation de l'entreprise de déposer d'autres rapports conformément à la Loi sur les Échanges prendra fin 90 jours après le dépôt du Formulaire 15.
Oncternal Therapeutics (ONCT) hat seine Absicht angekündigt, sich freiwillig von der Nasdaq abzulisten und sich bei der SEC abzumelden. Das Unternehmen plant, am 17. März 2025 ein Formular 25 zur Abmeldung einzureichen, nachdem der Handel mit den Stammaktien von ONCT am 3. Dezember 2024 zuvor von der Nasdaq ausgesetzt wurde.
Nachdem die Abmeldung wirksam wird, wird Oncternal ein Formular 15 zur Abmeldung bei der SEC einreichen, was sofort seine Verpflichtungen zur Einreichung von regelmäßigen Berichten, einschließlich der Formulare 10-K, 10-Q und 8-K, aussetzt. Die Verpflichtung des Unternehmens zur Einreichung anderer Berichte gemäß dem Exchange Act endet 90 Tage nach der Einreichung des Formulars 15.
- None.
- Voluntary delisting from Nasdaq stock exchange
- Trading suspension since December 3, 2024
- Termination of SEC reporting obligations
- Loss of major exchange visibility and liquidity
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on March 17, 2025, which will remove Oncternal's securities from listing and registration on Nasdaq, and to subsequently deregister with the Securities and Exchange Commission (“SEC”). Nasdaq previously suspended the trading of Oncternal’s common stock on December 3, 2024 and notified Oncternal that a Form 25 would be filed. However, as Nasdaq has not yet made the filing, Oncternal is doing so voluntarily to permit Oncternal to file a Form 15 to deregister with the SEC.
Once the Nasdaq delisting becomes effective, ten days later the Company will file a Form 15 to deregister with the SEC. Upon the filing of the Form 15, the Company’s obligation to file periodic reports with the SEC, including Forms 10-K, 10-Q, and 8-K, will be immediately suspended. The Company's duty to file any other reports required by the Exchange Act of 1934, as amended, with the SEC will be terminated 90 days after the filing of Form 15.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. More information on our company and programs is available at https://oncternal.com/.
Forward-Looking Information
Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Oncternal’s current beliefs and expectations. Forward-looking statements include statements regarding Oncternal’s intention to file a Form 15 and subsequently deregister with the SEC. Forward-looking statements are subject to risks and uncertainties inherent in Oncternal’s business, including Oncternal may delay filing the Form 15 and other risks described in Oncternal’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact Information:
Investors
Richard Vincent
858-245-8489
rvincent@oncternal.com
Business Development
Pablo Urbaneja
415-316-8276
purbaneja@oncternal.com
FAQ
When will Oncternal Therapeutics (ONCT) be delisted from Nasdaq?
What happens to ONCT shareholders after the Nasdaq delisting?
When was ONCT stock trading suspended on Nasdaq?
Will ONCT continue filing SEC reports after delisting?
